SNGX stock forecast
Our latest prediction for Soligenix, Inc.'s stock price was made on the April 22, 2019 when the stock price was at 0.71$.
In the short term (2weeks), SNGX's stock price should outperform the market by 5.56%. During that period the price should oscillate between -7.97% and +18.51%.
In the medium term (3months), SNGX's stock price should outperform the market by 10.47%. During that period the price should oscillate between -17.39% and +55.72%.Get email alerts
About Soligenix, Inc.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
At the moment the company generates 5M USD in revenues.
On its last earning announcement, the company reported a loss of -0.68$ per share.
The book value per share is 0.15$
Three months stock forecastApril 22, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|